SCHEMBL847849

SCHEMBL847849

[CH2]C(OC)(OCC)OCC

nearest known ligand 0.32

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.32
TSHR P16473 1/20 0.32
TDP1 Q9NUW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL691901 0.83
SCHEMBL692329 0.75
SCHEMBL8986723 0.71
SCHEMBL8538285 0.71
SCHEMBL9509371 0.69
SCHEMBL7894728 0.69 TDP1 (0.39) TDP1
SCHEMBL5073591 0.67 ADRB2 (0.36) ALDH1A1TSHR
SCHEMBL10646386 0.67 ADRB2 (0.36) ALDH1A1TSHR
SCHEMBL6547844 0.67
SCHEMBL128926 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024064962-A2 IMMUNO-PCR AND NEXT GENERATION SEQUENCING FOR PRECISE ANTIGEN QUANTITATION SLINGSHOT BIOSCIENCES, INC. (US) 2024-03-28 WO claimed
WO-2023094815-A1 SEPARATION MEMBRANE G2O WATER TECHNOLOGIES LIMITED (GB) 2023-06-01 WO claimed
US-8716530-B2 Facially amphiphilic polyaryl and polyarylalkynyl polymers and oligomers and uses thereof THE TRUSTESS OF THE UNIVERSITY OF PENNSYLVANIA (US) 2014-05-06 US claimed
CN-102027079-B Ink composition for optoelectronic device INKTEC CO LTD 2013-07-24 CN claimed
CN-101107257-B Organic silver complex, method for producing same, and method for forming thin layer using same INKTEC CO LTD 2012-11-07 CN claimed
CN-102702237-A Organic silver complex, method for producing same, and method for forming thin layer using same INKTEC CO LTD 2012-10-03 CN claimed
US-20120202887-A1 Facially Amphiphilic Polyaryl and Polyarylalkynyl Polymers and Oligomers and Uses Thereof THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2012-08-09 US claimed
CN-101511952-B Process for preparation of silver nanoparticles, and the compositions of silver ink containing the same INKTEC CO LTD 2012-07-25 CN claimed
EP-2468711-A2 Facially amphiphilic polyaryl and polarylalkynyl polymers and oligomers and uses thereof The Trustees Of The University Of Pennsylvania (US) 2012-06-27 EP claimed
CN-101678658-B Transparent conductive layer and preparation method thereof INKTEC CO LTD 2012-06-27 CN claimed
JP-2005530842-A 2005-10-13 JP claimed
WO-2005072246-A2 FACIALLY AMPHIPHILIC POLYARYL AND POLYARYLALKYNYL POLYMERS AND OLIGOMERS AND USES THEREOF THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2005-08-11 WO claimed
EP-1515705-A1 FLUOROSILOXANE MATRIX CONTROLLED DIFFUSION DRUG DELIVERY SYSTEM BAUSCH & LOMB INCORPORATED (US) 2005-03-23 EP claimed
US-20040202639-A1 Microbiocide surfaces; antiseptics; contact lenses, catheters NATIONAL SCIENCE FOUNDATION 2004-10-14 US claimed
EP-1372674-A4 FACIALLY AMPHIPHILIC POLYMERS AS ANTI-INFECTIVE AGENTS UNIV PENNSYLVANIA (US) 2004-05-12 EP claimed
WO-2004035012-A1 THE USE OF BIOMIMIC POLYMERS IN PERSONAL CARE COMPOSITIONS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2004-04-29 WO claimed
EP-1372674-A2 FACIALLY AMPHIPHILIC POLYMERS AS ANTI-INFECTIVE AGENTS UNIVERSITY OF PENNSYLVANIA (US) 2004-01-02 EP claimed
WO-2004000288-A1 FLUOROSILOXANE MATRIX CONTROLLED DIFFUSION DRUG DELIVERY SYSTEM BAUSCH & LOMB INCORPORATED (US) 2003-12-31 WO claimed
WO-2002072007-A2 FACIALLY AMPHIPHILIC POLYMERS AS ANTI-INFECTIVE AGENTS THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2002-09-19 WO claimed
US-5316704-A Deformed into elongation configuration; surgery insertion KABI PHARMACIA OPHTHALMICS INC. (US) 1994-05-31 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040202639-A1 Microbiocide surfaces; antiseptics; contact lenses, catheters POLR1C, CD74, ABHD16A ALDH1A1 3909/4885TSHR 2182/4885TDP1 2418/4885
US-20120202887-A1 Facially Amphiphilic Polyaryl and Polyarylalkynyl Polymers and Oligomers and Uses Thereof TLR3, ABHD16A, ANTXR2 ALDH1A1 4738/4885TSHR 1393/4885TDP1 3217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.